Edition:
United States

Deena Beasley

U.S. Senator Sanders urges FDA to allow older versions of $375,000 drug

Feb 28 2019

U.S. Senator Bernie Sanders this week urged regulators to allow pharmacies and manufacturers to resume distributing unbranded, lower-cost versions of a drug used to treat a rare neuromuscular disorder, according to a letter provided by his office to Reuters.

U.S. Senator Sanders urges FDA to allow older versions of $375K drug

Feb 28 2019

Feb 28 U.S. Senator Bernie Sanders this week urged regulators to allow pharmacies and manufacturers to resume distributing unbranded, lower-cost versions of a drug used to treat a rare neuromuscular disorder, according to a letter provided by his office to Reuters.

Novartis gene therapy would be cost effective up to $900,000: U.S. group

Feb 22 2019

An experimental gene therapy for spinal muscular atrophy (SMA) developed by Novartis AG would be worth up to $900,000, according to an independent U.S. nonprofit organization that reviews the value of drugs and medical treatments.

Novartis gene therapy is cost effective at up to $900,000 -U.S. group

Feb 22 2019

Feb 22 An experimental gene therapy for spinal muscular atrophy (SMA)developed by Swiss drugmaker Novartis AG would offer value at a price of $310,000 to $900,000, according an independent U.S. nonprofit organization that reviews the value of drugs and medical treatments.

U.S. Medicare plans to track CAR-T cancer therapy outcomes

Feb 15 2019

The U.S. Centers for Medicare & Medicaid Services (CMS) on Friday proposed coverage of expensive CAR-T cell therapies at cancer centers that meet criteria including a registry or clinical study to monitor how well patients fare for at least two years after treatment.

Gilead fourth-quarter profit misses Wall Street estimate, shares fall

Feb 04 2019

Gilead Sciences Inc on Monday reported a fourth-quarter profit that fell short of Wall Street estimates, sending shares lower, as sales of its flagship hepatitis C treatments continued to slide and it recorded one-time charges, and the company .

Gilead fourth-quarter profit misses Wall Street estimate, shares fall

Feb 04 2019

Feb 4 Gilead Sciences Inc on Monday reported fourth-quarter results that fell short of Wall Street estimates as sales of its flagship hepatitis C drugs continued to slide due to competition for a smaller pool of patients.

Amgen 2019 forecast falls short of expectations, shares dip

Jan 29 2019

Amgen Inc on Tuesday reported fourth-quarter profit that easily surpassed expectations as sales rose and tax expense fell, but competition for its older medicines is growing and the drugmaker forecast 2019 earnings below Wall Street estimates.

Amgen quarterly profit tops Street view, 2019 forecast falls short

Jan 29 2019

Jan 29 Amgen Inc on Tuesday reported higher-than-expected fourth-quarter profit as sales rose and tax expense fell, but competition for older medicines is growing and the drugmaker forecast 2019 earnings below Wall Street estimates.

World News